← Back to Clinical Trials
Recruiting NCT07386522

NCT07386522 Health Information for Persons With Spinal Cord Injury

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07386522
Status Recruiting
Phase
Sponsor Washington University School of Medicine
Condition Spinal Cord Injuries (SCI)
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2026-02-05
Primary Completion 2026-10-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Secondary Health Conditions (SHC) text message groupMotivational text message group

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2026-02-05 with a primary completion date of 2026-10-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this pilot study is to design and feasibility test a mobile phone text messaging (SMS) self-management intervention for persons with spinal cord injury (PwSCI). The project will focus on providing a 16-week text messaging intervention on the secondary health conditions of bowel/bladder management, pain, pressure injury, and psychosocial health. Our hopes are to reduce the impact of secondary health conditions (SHC) for PwSCI. The project hopes to test whether the developed self-management program will be feasible and superior to a control group. determine the feasibility and efficacy of the SMS intervention main questions the study aims to answer are: Participants will: Complete an initial assessment Participate in a 16-week text messaging program using their mobile phones Complete 4-week check-ins Complete a post assessment The main question\[s\] it aims to answer \[is/are\]: \[primary hypothesis or outcome measure 1\]? \[primary hypothesis or outcome measure 2\]? If there is a comparison group: Researchers will compare \[arm information\] to see if \[insert effects\]. Participants will \[describe the main tasks participants will be asked to do, interventions they'll be given and use bullets if it is more than 2 items\].

Eligibility Criteria

Inclusion Criteria: * 18 years of age or older * Diagnosis of SCI * At least 3 months from date of injury or illness * Identify at least one secondary health condition (pain, pressure injury, bladder/bowel dysfunction, and psychosocial distress) that impacts daily life * Live in the community * English as primary language * Ability and willingness to use their own smartphone to receive and respond to text messages for the 16-week study period * Ability and willingness to participate in two full assessments and an additional four check ins during the 16-week study period Exclusion Criteria: \- Current admission in a hospital or in-patient rehabilitation facility

Contact & Investigator

Central Contact

Kerri A Morgan, PhD

✉ morgank@wustl.edu

📞 314-286-1659

Principal Investigator

Kerri A Morgan, PhD

PRINCIPAL INVESTIGATOR

Washington University School of Medicine - Program in OT

Frequently Asked Questions

Who can join the NCT07386522 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Spinal Cord Injuries (SCI). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07386522 currently recruiting?

Yes, NCT07386522 is actively recruiting participants. Contact the research team at morgank@wustl.edu for enrollment information.

Where is the NCT07386522 trial being conducted?

This trial is being conducted at St Louis, United States.

Who is sponsoring the NCT07386522 clinical trial?

NCT07386522 is sponsored by Washington University School of Medicine. The principal investigator is Kerri A Morgan, PhD at Washington University School of Medicine - Program in OT. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology